BRICS Cryoablation Market (2022-2033)

The BRICS cryoablation market size is expected to reach US$ 892.1 million by 2033 from US$ 342.9 million in 2025. The market is estimated to record a CAGR of 12.7% from 2026 to 2033.

Executive Summary and BRICS Cryoablation Market Analysis:

The BRICS cryoablation market is shaped by a mix of emerging healthcare priorities, growing clinical expertise, and increasing demand for minimally invasive therapies. In this region Brazil, Russia, India, China, and South Africa, cryotherapy is being recognized for its precision and tissue-sparing benefits, particularly in oncology and cardiac care. China leads the region, benefiting from rapid expansion of specialized medical centers, advanced procedural infrastructure, and increasing clinician proficiency in interventional techniques. Other BRICS nations are gradually adopting cryoablation as awareness grows among physicians and patients, supported by focused training programs and improved hospital capabilities.

Despite the positive trajectory, market growth faces certain challenges. Differences in healthcare infrastructure, accessibility, and reimbursement frameworks across the BRICS countries create uneven adoption patterns. In less urbanized areas, limited availability of trained operators and procedural resources can restrict patient access. However, ongoing investments in healthcare modernization, clinical education, and patient awareness are gradually fostering a favorable environment for cryoablation, positioning the BRICS region as a promising area for long-term procedural growth and integration into standard care pathways.

BRICS Cryoablation Market - Strategic Insights:

BRICS Cryoablation Market Segmentation Analysis:

Key segments that contributed to the derivation of the BRICS cryoablation market analysis are product type, application, and end user.

• By product type, the cryoablation market is segmented into cryoablation systems, ablation probes and catheters, and consumables & accessories. The ablation probe and catheter segment dominated the market in 2025.
• Based on application, the cryoablation market is classified into cardiology, oncology, pain management, and other applications. The oncology segment dominated the market in 2025.
• In terms of end user, the cryoablation market is categorized into hospitals, specialty clinics, and ambulatory surgical centers. The hospitals segment dominated the market in 2025.

BRICS Cryoablation Market Drivers and Opportunities:

Upward Trend in Chronic Disease Occurrence

In the BRICS countries — Brazil, Russia, India, China, and South Africa — healthcare systems are confronting a noticeable rise in chronic health conditions that drive demand for advanced interventional treatments. Cardiac disorders, particularly arrhythmias that are challenging to manage with medications alone, are becoming more commonly treated in specialized centers. Cryoablation is gaining interest as a minimally invasive option that complements existing electrophysiology procedures in leading hospitals across these markets.

In Brazil, major cardiology institutes in São Paulo and Rio de Janeiro are increasingly performing ablation procedures as part of comprehensive cardiac care programs, reflecting a shift in clinical practice toward less invasive interventions. Similarly, in Russia and China, urban cardiology departments are expanding their procedural portfolios to include advanced ablation tools to meet the needs of aging populations experiencing more complex forms of heart disease. In India and South Africa, private tertiary care facilities are also introducing cryoablation alongside conventional therapies to serve patients seeking reduced downtime after treatment.

Chronic conditions beyond cardiac disease are also shaping demand. Oncology teams in BRICS nations are exploring focal therapies that allow for the treatment of select tumors without extensive surgery, aligning with the broader trend of adopting minimally invasive approaches. As chronic illnesses become more prevalent across BRICS healthcare landscapes, clinicians and hospital administrators are increasingly recognizing cryoablation as a strategic addition to procedural offerings that can address evolving patient needs.

Pursuing Additional Clinical Opportunities

While cryoablation’s initial adoption in BRICS has focused predominantly on cardiac arrhythmia management, clinical interest is broadening into other therapeutic areas. In China and India, interventional radiologists and oncology specialists are evaluating cryoablation for soft-tissue and organ-specific applications, particularly for patients who are not ideal candidates for standard surgical resection. This reflects an overall willingness among clinicians to explore the technology’s utility beyond its traditional niche.

Oncology units in Brazil and South Africa are incorporating cryoablation into multidisciplinary care strategies for localized tumors, using image-guided approaches to target diseased tissue with precision. These efforts allow clinicians to offer additional options for patients seeking less invasive treatments with potentially shorter recovery times. In several metropolitan treatment centers, cryoablation is now part of case discussions alongside other ablation modalities and interventional therapies.

Emerging uses in pain management and palliative care are also gaining traction in BRICS markets. Clinicians are experimenting with cryoablation for nerve-related pain conditions, leveraging its ability to target specific anatomic areas with minimal collateral injury. While these indications are still in development compared with cardiac and oncology applications, they show the expanding interest in using cryoablation across a wider range of clinical scenarios. As procedural expertise and technology access grow across BRICS healthcare systems, the market is expected to embrace these broader clinical opportunities.

BRICS Cryoablation Market Size and Share Analysis:

The BRICS cryoablation market demonstrates steady growth, with size and share analysis highlighting evolving trends and competitive dynamics among key players. The report evaluates important subsegments categorized within product type, application, and end user, highlighting their respective contributions to overall market performance.

By product type, the ablation probe and catheter subsegment dominated the market in 2025. This is driven by the recurring need for precise and reliable probes and catheters during cryoablation procedures, essential for effective freezing and destruction of targeted tissues, making them a key revenue driver for manufacturers and ensuring consistent demand in clinical settings.

In terms of application, the oncology subsegment dominated the market in 2025. The leadership of oncology applications is attributed to the rising incidence of cancer cases, growing preference for minimally invasive tumor ablation techniques, and increasing awareness among healthcare providers about the effectiveness of cryoablation in treating liver, kidney, prostate, and other solid tumors.

Based on end user, the hospitals subsegment dominated the market in 2025. Hospitals maintain a stronghold due to their well-established oncology and surgical departments, access to advanced cryoablation equipment, trained interventional radiologists and staff, and the capability to perform complex procedures with comprehensive patient care.

BRICS Cryoablation Market Report Highlights:

BRICS Cryoablation Market Report Coverage and Deliverables:

The "BRICS Cryoablation Market Size and Forecast (2022–2033)" report provides a detailed analysis of the market covering below areas:

• BRICS Cryoablation market size and forecast at regional, and country levels for all market segments covered under the scope
• BRICS Cryoablation market trends, as well as drivers, restraints, and opportunities
• BRICS Cryoablation market analysis covering key trends, regional framework, major players, regulations, and recent developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the BRICS Cryoablation market
• Detailed company profiles, including SWOT analysis

BRICS Cryoablation Market Geographic Insights:

The geographical scope of the BRICS cryoablation market report is divided into: Russia, Brazil, South Africa, India, China, Egypt, Indonesia, Saudi Arabia, and the UAE. China held the largest share in 2025.

China dominates the BRICS cryoablation market due to its advanced healthcare infrastructure and strategic focus on minimally invasive therapies. Leading hospitals in major cities have integrated cryoablation into treatment protocols for both oncology and cardiac conditions, offering a precise, tissue-sparing alternative to conventional surgical interventions. The development of specialized clinical centers and multidisciplinary teams ensures that patient selection, procedural planning, and post-operative care are effectively coordinated. Clinician training and adoption of imaging-guided cryoablation have strengthened procedural confidence, while patient demand for less invasive therapies has increased institutional support for these technologies. Regional disparities remain, with urban hospitals benefiting more from advanced procedural capabilities than rural areas, but China’s focus on healthcare modernization, innovation, and professional education continues to reinforce its leadership in cryoablation adoption within the BRICS region.

BRICS Cryoablation Market Research Report Guidance:

• The report includes qualitative and quantitative data in the BRICS Cryoablation market across product type, application, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the BRICS Cryoablation market.
• Chapter 3 focuses on the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the BRICS Cryoablation market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the BRICS Cryoablation market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 10 cover the BRICS Cryoablation market segments by product type, application, end user, and geography across Russia, Brazil, South Africa, India, China, Egypt, Indonesia, Saudi Arabia, and the UAE. They cover the market revenue, forecast, and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 12 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 13 provides detailed profiles of the major companies operating in the BRICS Cryoablation market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 14, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

BRICS Cryoablation Market News and Key Development:

The BRICS cryoablation market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the BRICS cryoablation market are:

• In January 2025, IceCure Medical Ltd. announced that it submitted a regulatory filing with China’s National Medical Products Administration (NMPA) seeking approval for its ProSense Cryoablation System — expanding beyond its already-approved disposable cryoprobes to seek full product clearance for broader clinical indications in China, one of the largest healthcare markets in the BRICS group.
• In September 2023, IceCure Medical Ltd. announced that its ProSense Cryoablation System received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA) as a Class III medical device for the treatment of benign and malignant tissue in multiple indications including breast, prostate, kidney, lung, liver, musculoskeletal, and skin, enabling formal marketing and sales of ProSense and its accessories in Brazil, the largest LATAM market in the BRICS.

Key Sources Referred:

• The World Bank
• World Health Organization (WHO)
• Center for Disease Control and Prevention (CDC)
• Food and Drug Administration (FDA)
• European Database on Medical Devices (EUDAMED)
• European Society of Cardiology (ESC)
• American College of Cardiology (ACC)
• American Heart Association (AHA)
• Company Websites
• Company Annual Reports
• Company Investor Presentations